Jefferies Cuts Numbers on Endo Pharmaceuticals (ENDP); Lots of Moving Parts But Expect Q1 Weakness
ENDP Hot Sheet
Rating Summary:9 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
Jefferies maintains a 'Buy' on Endo Pharmaceuticals (NASDAQ: ENDP) price target lowered from $54 to $48.
Jefferies analyst says, "Although we are lowering numbers, we still have ENDP as one of our top 3 picks in front of what could be a Lidoderm settlement and underappreciated Opana TR opportunity. It should not be a surprise given the manufacturing mess already announced, but we want investors to realize that shortages of Opana and Voltaren Gel will likely have a material impact on Q1. Hence our new $0.82 is 40 cents below consensus of $1.22."
Jefferies cuts FY12 EPS estimate from $5.63 to $5.54 and FY13 from $6.76 to $6.08.
For an analyst ratings summary and ratings history on Endo Pharmaceuticals click here. For more ratings news on Endo Pharmaceuticals click here.
Shares of Endo Pharmaceuticals closed at $37.73 yesterday, with a 52 week range of $26.02-$44.53.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
Jefferies analyst says, "Although we are lowering numbers, we still have ENDP as one of our top 3 picks in front of what could be a Lidoderm settlement and underappreciated Opana TR opportunity. It should not be a surprise given the manufacturing mess already announced, but we want investors to realize that shortages of Opana and Voltaren Gel will likely have a material impact on Q1. Hence our new $0.82 is 40 cents below consensus of $1.22."
Jefferies cuts FY12 EPS estimate from $5.63 to $5.54 and FY13 from $6.76 to $6.08.
For an analyst ratings summary and ratings history on Endo Pharmaceuticals click here. For more ratings news on Endo Pharmaceuticals click here.
Shares of Endo Pharmaceuticals closed at $37.73 yesterday, with a 52 week range of $26.02-$44.53.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays Cuts PT and Estimates on Dell (DELL); Apple's (AAPL) Momentum Proves Disrupting
- Nomura Securities Sees Trends Continuing To Be Difficult at Wet Seal, Inc. (WTSLA); Cutting FY12/13 Estimates
- Barclays Raises Estimates on PetSmart (PETM); Expect Continued Momentum Despite Challenging Macro
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
